Matching-Adjusted Indirect Comparison (MAIC) of Deucravacitinib Versus Adalimumab for the Treatment of Patients With Moderate to Severe Plaque Psoriasis over 2 Years. J of Skin 2023, 7 (2), s112. https://doi.org/10.25251/skin.7.supp.112.